Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early sitagliptin to prevent new-onset diabetes after kidney transplantation
ChiCTR2300072158Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in post-transplantation diabetes mellitus (PTDM) comparing Sitagliptin early-initiation arm with Standard-of-care control arm (2 arms). Primary endpoint: Incidence of new-onset diabetes after transplantation at 1 year. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
sitagliptin
03
Conditions
post-transplantation diabetes mellitus (PTDM)
Beyond the preview
Go deeper on ChiCTR2300072158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072158.